Beyond the black box: drug- and device-associated hypersensitivity events by Bennett, Charles L et al.
© 2010 Bennett et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Drug, Healthcare and Patient Safety 2010:3 1–5
Drug, Healthcare and Patient Safety

M i n i   –   r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Beyond the black box: drug- and device-associated 
hypersensitivity events
Charles L Bennett1,2 
Olatokunbo S Adegboro2 
elizabeth A Calhoun2 
Dennis raisch3,4
1Jesse Brown vA Medical Center, 
Chicago, iL, USA; 2University 
of illinois School of Public 
Health, Chicago, iL, USA; 
3University of new Mexico 
College of Pharmacy, Albuquerque, 
nM, USA; 4veteran Affairs 
Cooperative Studies Program, 
Clinical research Pharmacy, 
Albuquerque, nM, USA
Correspondence: Charles Bennett 
Senior research Associate/Associate 
Professor, Lakeside vAMC/northwestern 
University, Medical Sciences Building, 400 
east Ontario Street, Chicago, iL 60611, USA 
email charlesleebennett@gmail.com
Background: Drug- and device-associated hypersensitivity reactions are serious toxicities that 
can result in respiratory failure or acute cardiac ischemic events, or even severe hypersensitivity 
syndromes such as Stevens–Johnson syndrome. These toxicities are usually poorly described 
in the “black box” warnings section of the product labels.
Methods: Adverse event reports contained in databases maintained by the Project on Medical 
Research on Adverse Drug Events and Reports (Med-RADAR), product labels, safety advisories 
disseminated by pharmaceutical manufacturers, the Food and Drug Administration (FDA), and 
the Centers for Disease Control and Prevention (CDC) were reviewed.
Results: Adverse event reports identified three health care workers who developed nevirapine-
associated Stevens–Johnson syndrome following occupational exposure to HIV-infected blood or 
blood products; four persons with localized hypersensitivity and fatal cardiac events associated 
with rapamycin- or paclitaxel-coated coronary artery stent placements; and six persons with 
breast cancer who developed severe or fatal anaphylaxis after receiving adjuvant chemotherapy 
with Cremophor-EL containing paclitaxel. Safety advisories from the FDA, CDC, and the rel-
evant pharmaceutical manufacturers were ambiguous in their description in “black box” warning 
sections of package inserts describing these serious and potentially fatal toxicities.
Conclusion: Improvements are needed in pharmacovigilance and subsequent dissemination 
of safety advisories for drug/device-associated hypersensitivity reactions.
Keywords: adverse events, hypersensivity, toxicity, drug
Introduction
Hypersensitivity reactions range in severity from mild pruritus to systemic anaphylaxis, 
and can result in potentially severe clinical outcomes, including respiratory arrest, 
cardiac collapse, and death.1 There are four basic types of hypersensitivity reactions.2 
Type I (immediate) hypersensitivity involves cell-fixed antibody, mainly immuno-
globulin E (IgE) attached to mast cells or basophils. Antigen binding causes the cell 
to release vasoactive factors. Type II (antigen-dependent cellular cytotoxicity) hyper-
sensitivity causes cytotoxicity by interactions of immunoglobulins with complement or 
cytotoxic cells. Type III (immune-complex or subacute) hypersensitivity causes tissue 
damage and inflammation by deposition of antigen-antibody complexes that activate 
complement and attract polymorphonuclear cells. Type IV (delayed hypersensitivity) 
involves sensitized T lymphocytes that interact with cell bound or associated antigen 
and release lymphokines, causing mononuclear cell accumulation, tissue damage and 
inflammation. This hypersensitivity typically occurs at least 24 hours after exposure 
to the antigen.Drug, Healthcare and Patient Safety 2010:3 
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For several reasons, hypersensitivity-associated adverse 
drug events are particularly difficult to identify as part of 
routine pharmacovigilance initiatives conducted by the 
Food and Drug Administration (FDA) or pharmaceutical 
manufacturers. Spontaneous case descriptions are poorly 
described in the FDA’s Adverse Event Reporting System 
(AERS) database or the Manufacturer and User Facility 
Device Experience (MAUDE) database, the primary phar-
maceutical and device safety databases, respectively, used 
by the FDA.3,4 Unless the adverse event incidence rate is 
very high or the clinical outcome severe or fatal, registra-
tional clinical trial safety databases often will not contain 
many reports of these events. In other clinical trials, similar 
underreporting is likely to occur. In contrast, active phar-
macovigilance initiatives can provide valuable information 
on drug-associated hypersensitivity events characterized by 
very comprehensive and low quantity case reports. Over the 
past decade, databases maintained by the Medical Research 
on Adverse Drug Events and Reports (Med-RADAR) 
project have focused in part on this toxicity.5,6 Herein, we 
describe these database findings and associated safety-
related dissemination media, and outline the implications 
of these findings.
Methods
Med-RADAR databases were created by National Insti-
tutes of Health-funded R01 and American Cancer Society 
research grants.5,6 These databases contain detailed informa-
tion on severe or potentially fatal adverse drug reactions. 
In most instances, the incidence rates of these events are 
low, but the clinical outcomes are severe. It is staffed by 
25 co-investigators worldwide with background and expertise 
in clinical medicine, epidemiology, pharmacology, infec-
tious diseases, oncology, hematology, pharmacy, and public 
policy. Databases evaluated in Med-RADAR investigations 
include MAUDE, MedWatch, spontaneous reports from 
physicians, active surveillance efforts, clinical trial reports, 
and case series reviews. To date, 43 distinct serious adverse 
drug reactions, including: thienopyridine-associated throm-
botic thrombocytopenic purpura; epoetin-associated pure 
red cell aplasia, venous thromboembolism, and mortality; 
and rituximab-associated progressive multifocal leucoen-
cephalopathy, have been identified and described in reports 
based on evaluations of Med-RADAR databases.5,6 Causal 
association grades were assigned according to World Health 
Organization (WHO) criteria.7 These criteria classify causal 
associations as certain, probable, possible, or unlikely based 
on timing, pathophysiology, de-challenge (agent withdrawal), 
re-challenge (agent re-exposure), and competing explanations. 
Additional data sources included product labels, primarily 
“black box” label sections, and safety advisories dissemi-
nated by the FDA and pharmaceutical manufacturers.
Results
Med-RADAR databases were used to identify and report 
information on four distinct drug-associated hypersensi-
tivity reactions: nevirapine-associated Stevens–Johnson 
syndrome, Cremophor-EL containing paclitaxel-associated 
anaphylaxis among breast cancer patients receiving adjuvant 
chemotherapy, and paclitaxel- and sirolimus-eluting coronary 
artery stent associated hypersensitivity7–9 (Table 1). These 
four events are characterized by their severity and by the 
difficulty associated with identifying relevant comprehensive 
clinical reports in traditional safety data sources maintained 
by the FDA or the pharmaceutical supplier.
Detailed information in the Med-RADAR databases 
is available for 13 individuals with these hypersensitivity 
reactions (Table 2). The clinical richness of these safety 
reports is evident as shown in information on patient 
sociodemographics, time to onset, administration of pro-
phylaxis, presenting clinical findings, and outcome. For the 
drug-eluting stents coated with paclitaxel or rapamycin, 
autopsy materials supported the clinical diagnosis of local-
ized hypersensitivity. Time to onset ranged from minutes 
(Cremophor-EL-containing paclitaxel), to within two weeks 
(nevirapine-administration to non-HIV-infected individuals 
following HIV exposure), to several weeks (coronary artery 
drug-eluting stents). Severe nonfatal anaphylaxis occurred 
in seven individuals (three non-HIV-infected health care 
workers who received nevirapine and four women with 
breast cancer who received adjuvant chemotherapy with 
Cremophor-EL-containing paclitaxel), while death occurred 
in six individuals (four persons with coronary artery disease 
who received coronary artery drug-eluting stents and two 
women with breast cancer who received Cremophor-EL-
containing paclitaxel-based adjuvant chemotherapy). Of note, 
symptoms manifested primarily as Stevens–Johnson syn-
drome with dermatologic findings (nevirapine), severe 
respiratory failure (Cremophor EL-containing paclitaxel), 
or acute coronary events (paclitaxel- and sirolimus-eluting 
coronary artery stents).
Causality assessment is particularly difficult when 
evaluating serious hypersensitivity-like clinical events that 
occur following administration of a drug. The validated 
WHO classification system characterizes the Cremophor 
EL-containing paclitaxel events as probable based on timing, Drug, Healthcare and Patient Safety 2010:3 
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pathophysiology and absence of competing explanations, the 
paclitaxel- and sirolimus-containing cardiac stent events as 
probable based on pathophysiology and autopsy findings, 
and the nevirapine-associated Stevens–Johnson syndrome 
as probable based on timing, pathophysiology, and absence 
of competing explanations. “Black box” warnings were dis-
seminated by the pharmaceutical manufacturers for three 
of the four products (the exception being hypersensitivity 
associated with paclitaxel-coated cardiac stents), although 
clinical information on effective strategies to prevent, diag-
nose, and treat these reactions as well as epidemiologic rate 
estimates was lacking (Table 3). Public health advisories from 
the manufacturer and the FDA have been disseminated for 
hypersensitivity associated with nevirapine- and sirolimus-
eluting coronary artery stents, although the warning for 
the drug stents was retracted by the FDA one month after 
issuance.
Discussion
Hypersensitivity is a serious and occasionally fatal adverse 
drug reaction. Med-RADAR databases include detailed 
clinical information on 13 individuals who developed 
severe drug-associated hypersensitivity associated with four 
drugs/devices. Despite the small number of clinical reports 
contained in these databases, peer-reviewed publications 
containing detailed clinical information have been dissemi-
nated for each of these adverse drug reactions. In contrast, 
“black box” warnings for these adverse reactions contain 
incomplete and often inconsistent clinical and epidemiologic 
findings. In interpreting our findings, several factors should 
be considered.
Causality assessment for hypersensitivity reactions 
is challenging. With the paclitaxel- and sirolimus-coated 
coronary artery stents, the associated FDA and manufac-
turer warnings have been ambiguous.10,11 However, the 
Med-RADAR-related publication with autopsy findings 
identifying local inflammatory infiltrates for four patients 
provides support for causality. For the Cremophor-EL-
containing paclitaxel, nonimmune-mediated activation of 
the complement system is one possible mechanism. How-
ever, Cremophor-EL can cause histamine release from mast 
cells (this is most likely an IgE-mediated event), and result 
in acute pulmonary toxicity.12–14 Similar hypersensitivity 
reactions have not been reported with a Cremophor-free 
formulation of paclitaxel that received FDA approval in 
2005.15 For the nevirapine-associated hepatotoxicity among 
non-HIV-infected health care workers, a contemporaneous 
report from England identified five similar cases among 41 
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non-HIV-infected individuals after occupational or sexual 
exposure to HIV .16
Improved dissemination of safety information to clinicians 
and patients is essential.17 As noted above, “black box warn-
ings” were disseminated for three of the adverse reactions 
and pharmaceutical manufacturers disseminated safety advi-
sories for two of the adverse drug reactions. However, the 
FDA retracted their safety advisory for the sirolimus-coated 
coronary artery stent-associated hypersensitivity one month 
after issuance. The manufacturer of nevirapine disseminated 
safety alerts for nevirapine-associated hypersensitivity to 
clinicians in 2003, two years after the Centers for Disease 
Control disseminated a safety advisory describing associ-
ated clinical findings in the Morbidity and Mortality Weekly 
Report.18 While recent FDA initiatives include improved 
mechanisms for disseminating comprehensive and timely 
safety information, empirical evidence that these mecha-
nisms are effective is lacking.19 In particular, improvements 
Table  Detailed case history of Med-RADAR reports for serious drug-associated hypersensitivity reactions classified as certain or 
probable according to the WHO classification system
Drug  Clinical finding  Outcome  Age  Gender  Time to onset  Prophylaxis  
administered
Publication reference 
Cremophor-eL-
containing Paclitaxel
Anaphylaxis Death 37 Female 10 minutes Yes Community Oncology 2009
Cremophor-eL-
containing Paclitaxel
Anaphylaxis Death 38 Female nA Yes Community Oncology 2009
Cremophor-eL-
containing Paclitaxel
Anaphylaxis recovered 34 Female 10 minutes Yes Community Oncology 2009
Cremophor-eL-
containing Paclitaxel
Anaphylaxis recovered 39 Female 10 minutes Yes Community Oncology 2009
Cremophor-eL-
containing Paclitaxel
Anaphylaxis recovered 48 Female 10 minutes Yes Community Oncology 2009
Cremophor-eL-
containing Paclitaxel
Anaphylaxis recovered 54 Female 20 minutes Yes Community Oncology 2009
Paclitaxel-coated 
cardiac stent
Localized 
hypersensitivity
Death nA nA 30 days no Journal of the American College  
of Cardiology 2006
rapamycin-coated 
cardiac stent
Localized 
hypersensitivity
Death nA nA 78 days no Journal of the American College  
of Cardiology 2006
rapamycin-coated 
cardiac stent
Localized 
hypersensitivity
Death nA nA 150 days no Journal of the American College  
of Cardiology 2006
rapamycin-coated 
cardiac stent
Localized 
hypersensitivity
Death 58 Male 21 days no Journal of the American College  
of Cardiology 2006
nevirapine Stevens–Johnson recovered 27 Female 7 days no Annals of Internal Medicine 2002
nevirapine Stevens–Johnson recovered 38 Male 9 days no Annals of Internal Medicine 2002
nevirapine Stevens–Johnson recovered 41 Male 11 days no Annals of Internal Medicine 2002
Abbreviation: nA, not available.
Table  Manufacturer- and FDA-disseminated warnings related to drug-related serious hypersensitivity adverse events based on reports 
included in Med-rADAr databases
Drug  Toxicity  Package insert  
warning
FDA-disseminated  
public health advisory
Manufacturer-disseminated   
public health advisory
Cremophor eL-containing 
paclitaxel
Anaphylaxis Black box (2001) none none
Paclitaxel-containing 
cardiac stent
Localized hypersensitivity Black box (2003) none none
rapamycin-containing 
cardiac stent
Localized hypersensitivity 
and subacute coronary 
artery thrombosis
none 2003 (retracted one 
month later)
Dear Colleague (2003)
nevirapine Stevens–Johnson Syndrome Black box (2002) 2003 2003
Abbreviation: FDA, US Food and Drug Administration.Drug, Healthcare and Patient Safety 2010:3
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in approaches to disseminating important information that 
is briefly outlined as “black box” warnings are needed. 
Woolshin and colleagues recently described an improved 
“facts box” to facilitate comprehensive, yet concise informa-
tion on both risks and benefits of drugs.20
Strategies to prevent hypersensitivity reactions from 
occurring also deserve consideration (Table 1). For post-
exposure prophylaxis following occupational exposure to 
HIV-infected blood or blood products, the United States 
Public Health Services has identified six antiretroviral agents 
(abacavir, delavirdine, zalcitabine, didanosine with stavudine, 
and nevirapine) that should not be administered because of 
toxicity considerations. For women with breast cancer, the 
cremophor-EL-free formulation of paclitaxel has a high 
efficacy and no evidence of hypersensitivity. For drug-eluting 
coronary artery stents, concern over late thrombotic events 
has resulted in increased usage of bare metal stents.
In summary, Med-RADAR database efforts focusing on 
drug/device-associated hypersensitivity reactions resulted 
in dissemination of safety information for two drugs and 
two devices through peer-reviewed publications in medical 
journals, although detailed descriptions of these toxicities 
were not disseminated by the manufacturers or the FDA.
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